--- title: "截止日期临近：损失资金的 Regencell Bioscience Holdings Limited（RGC）股东被敦促联系 Howard G. Smith 律师事务所" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/285598129.md" description: "呼吁在 2026 年 6 月 23 日截止日期之前遭受损失的 Regencell Bioscience Holdings Limited (RGC) 股东联系霍华德·G·史密斯律师事务所，以提交证券欺诈诉讼的首席原告动议。该诉讼源于 Regencell 披露了对其交易行为的司法部调查，这导致股价大幅下跌。2024 年 10 月 28 日至 2025 年 10 月 31 日期间购买股票的投资者可能有资格参与集体诉讼" datetime: "2026-05-07T18:25:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285598129.md) - [en](https://longbridge.com/en/news/285598129.md) - [zh-HK](https://longbridge.com/zh-HK/news/285598129.md) --- # 截止日期临近：损失资金的 Regencell Bioscience Holdings Limited（RGC）股东被敦促联系 Howard G. Smith 律师事务所 **Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith** Law Offices of Howard G. Smith reminds investors of the upcoming **June 23, 2026** deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between **October 28, 2024 and October 31, 2025**, inclusive (the “Class Period”). **IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.** Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. **What Happened?** On October 31, 2025, Regencell disclosed that “following recent volatility in the market for \[its\] Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice (‘DOJ’), indicating that the DOJ is conducting an investigation into the trading in \[its\] Ordinary Shares.” The Company further stated that “\[t\] he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters” and that the Company “expect\[s\] to continue to incur significant legal costs and other expenses in connection with responding to the investigation” and “may be required to pay fines, penalties, damages or settlement costs in excess of \[its\] insurance coverage, if any, related to the investigation.” On this news, Regencell’s stock price fell $3.09, or 18.56%, to close at $13.56 per share on November 3, 2025, thereby injuring investors. **What Is The Lawsuit About?** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Regencell was vulnerable and/or subject to market manipulation; (2) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; (3) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Regencell securities during the Class Period, you may move the Court no later than **June 23, 2026** to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. **Contact Us To Participate or Learn More:** If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@howardsmithlaw.com, Visit our website at: www.howardsmithlaw.com. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 howardsmith@howardsmithlaw.com www.howardsmithlaw.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260507450867/en/ ### 相关股票 - [RGC.US](https://longbridge.com/zh-CN/quote/RGC.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) ## 相关资讯与研究 - [“搞钱”，才是 Revolution 千亿神话密码](https://longbridge.com/zh-CN/news/286888792.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md) - [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md) - [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md)